Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.

Elie RitchSimon Y F FuCameron HerbertsGang WangEvan W WarnerElena SchönlauSinja TaavitsainenAndrew J MurthaGillian VandekerkhoveKevin BejaYulia LoktionovaDaniel J KhalafLadan FazliIgal KushnirCristiano FerrarioSebastien HotteMatti AnnalaKim N ChiAlexander W Wyatt

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Hypermutated MMRd mPC is associated with oncogene activation and subclonal diversity, which may contribute to a clinically aggressive disposition in selected patients. In patients with detectable ctDNA, cell-free DNA sequencing is a practical tool to prioritize this subtype for immunotherapy.See related commentary by Schweizer and Yu, p. 981.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
squamous cell carcinoma
small cell lung cancer
chronic kidney disease
radical prostatectomy
circulating tumor
single cell
patient reported
drug induced
circulating tumor cells